WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its… Click here to view original post… […]
WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that management will host a conference call to highlight interim data from its ongoing Phase… Click here to view original post… […]
WATERTOWN, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that a late-breaking abstract highlighting topline data for the Phase 1 DAVIO trial of EYP-1901… Click here to view original post… […]
WATERTOWN, Mass., July 20, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company expects to receive a nine month extension on DEXYCU®’s pass-through payment… Click here to view original post… […]
WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company will be added to the small-cap Russell 2000® Index and the… Click here to view original post… […]
Copyright © 2022 Biotech Networks, LLC
